If approved by the European Commission (EC), Repatha would be the first PCSK9 inhibitor in Europe with the option of a single monthly injection. Repatha was the first PCSK9 inhibitor to gain marketing ...

Amgen (AMGN) said new findings from a pre-specified Phase 3 VESALIUS-CV trial analysis showed Repatha (evolocumab) reduced the risk of death by 20% in high-risk adults without a prior heart attack or ...

Amgen Inc. AMGN announced that the FDA has approved a new, monthly single-dose administration option for its PCSK9 inhibitor, Repatha. The Repatha Pushtronex system, an on-body infusor with a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Amgen's Repatha reduces risk of death in patients at high risk for a first heart attack or stroke: Thousand Oaks, California Tuesday, September 1, 2026, 18:00 Hrs [IST] Amgen anno ...

THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...

Amgen (NASDAQ: AMGN) announced that CVS Health (NYSE:CVS) will provide preferred access to Repatha® (evolocumab) through its CVS/caremark commercial formularies. "Ensuring access to Repatha for ...

Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price. This move comes as part of a broader response ...

The government’s approval of a new drug to lower cholesterol could mean billions of dollars for Thousand Oaks biotech giant Amgen — and spark a new round of debate over the thousands of dollars it ...